Biotechnology

Thursday Apr 25, 2024 - 9:39 am

InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Engages IBN for Corporate Communications Expertise

Nutriband (NASDAQ: NTRB, NTRBW), a pharmaceutical company with a special focus on transdermal technologies, today announced that it has selected IBN, a multifaceted financial news and publishing company for private and public entities, to assist with its corporate communications initiatives. According to the announcement, Nutriband’s AVERSA(TM) technology can be incorporated into any transdermal patch and includes aversive agents to prevent abuse, diversion, misuse and accidental…

Thursday Apr 25, 2024 - 9:10 am

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Abstract to Be Presented Next Month at ASCO Annual Meeting

Predictive Oncology (NASDAQ: POAI), a leader in artificial-intelligence (“AI”)-driven drug discovery and biologics, announced that its abstract has been accepted for presentation at the upcoming American Society of Clinical Oncology (“ASCO”) annual meeting. This year’s meeting is slated for May 31–June 4, 2024, in Chicago. According to the company, the abstract contains data and results gathered from a recent study completed through a collaboration between…

Wednesday Apr 24, 2024 - 12:03 pm

InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Update on Plan of Arrangement with Exopharm Limited

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, today announced that shareholders of Exopharm Limited ACN 163 765 991 approved a previously announced plan of arrangement between Exopharm Limited and Tryp (the “parties”). The announcement confirmed that all conditions precedent to the completion of the arrangement…

Wednesday Apr 24, 2024 - 11:41 am

InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Closes $8.4M Private Placement

Nutriband (NASDAQ: NTRB, NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that it has closed an $8.4 million private placement to fund the commercial development program for its lead product, AVERSA(TM) Fentanyl. AVERSA Fentanyl has the potential to be the world’s first abuse-deterrent opioid patch designed to deter the abuse and misuse and reduce the risk of accidental exposure…

Wednesday Apr 24, 2024 - 9:20 am

InvestorNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Completes Key Step in Preparation of PAX-101 for NDA Submission to FDA

PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, has made a key announcement regarding the development of its proprietary PAX-101, an IV formulation of suramin. According to the announcement, the company has completed execution of three pivotal registration/validation batches of PAX-101. The company noted that the completion is an “important milestone” in enabling a New Drug Application (“NDA”) submission to…

Tuesday Apr 23, 2024 - 1:54 pm

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO to Present at LSX World Congress 2024

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has announced that its Chief Executive Officer John Climaco will present at the LSX World Congress 2024. Climaco is slated to present at 4:15 PM (GMT+1) on Monday, April 29, 2024, at the event taking place in London, England.…

Tuesday Apr 23, 2024 - 12:33 pm

InvestorNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Responds to Emergency Request for IV Suramin, Commits to Provide Immediate Access to PAX-101

PaxMedica (NASDAQ: PXMD), a leading biopharmaceutical company dedicated to advancing treatments for neurological disorders, expects to take immediate action in response to an urgent request for IV suramin from the Ministry of Health (“MOH”) of Malawi, a country in east Africa. The request seeks emergency access to PaxMedica’s recently completed registration batches of PAX-101 (“IV suramin”) to address the critical shortage of medications required to…

Tuesday Apr 23, 2024 - 9:56 am

InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Enters Exclusive Supplier Agreement with Major Sports Brand Licensee

Nutriband (NASDAQ: NTRB, NTRBW) today announced that following its engagement by Fit For Life Group (“FFL”), a major brand license holder, on April 19, 2024, the companies fully executed an exclusive supplier agreement for FFL’s new product launch under one of its top brands. According to the announcement, Nutriband’s wholly owned contract manufacturing subsidiary, Active Intelligence, will act as manufacturer. Founded in 2016, FFL has…

Friday Apr 19, 2024 - 1:34 pm

InvestorNewsBreaks – Astiva Health Is Redefining Senior Healthcare

Astiva Health, a leading healthcare provider that specializes in delivering personalized and comprehensive healthcare solutions to diverse communities, is pioneering transformative healthcare for seniors, with a focus on enhancing mobility and promoting independence. “Central to Astiva Health’s mission is empowering seniors to engage actively in their healthcare decisions, supporting their flourishing in later years… Astiva Health is committed to empowering seniors through customized exercise programs…

Friday Apr 19, 2024 - 9:13 am

InvestorNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Closes on Multimillion-Dollar Warrant Exercise Offering, Public Offering

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty, has closed on its warrant exercise offering. According to the announcement, the exercise comprised certain existing warrants to purchase 2,399,744 shares of LGVN Class A common stock; the warrants were originally issued in October 2023 and April…

Thursday Apr 18, 2024 - 10:48 am

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Welcomes Leading Authority in Alzheimer’s Research to Scientific Advisory Board

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, is announcing that Dr. David G. Morgan, PhD, a renowned leader in neurodegenerative disease, has joined its scientific advisory board (“SAB”). The announcement noted that the addition reinforces the company’s commitment to advancing its INM-901 program in the treatment of Alzheimer’s disease. Dr. Morgan is the…

Thursday Apr 18, 2024 - 10:13 am

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Research Published in “Journal of Medicinal Chemistry”

Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation, psychedelic-based treatment options, is reporting that its research has been published in a prestigious biweekly, peer-reviewed publication. Titled “Synthesis and Structure-Activity Relationships of 2,5-dimethoxy-4-substituted phenethylamines and the discovery of CYB210010: A potent, orally bioavailable and long-acting serotonin 5-HT 2 receptor agonist,” the research manuscript has…

Wednesday Apr 17, 2024 - 10:43 am

InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) to Exercise Warrants for ~$6.2M

Longeveron (NASDAQ: LGVN) is a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-related Frailty. The company today announced its entry into definitive agreements for the exercise of certain existing warrants to purchase an aggregate of 2,399,744 shares of its Class A common stock having an exercise price of $2.35…

Wednesday Apr 17, 2024 - 9:47 am

InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Study Results for CNM-Au8 as Multiple Sclerosis Treatment Presented at AAN Conference

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company, and its wholly owned subsidiary Clene Nanomedicine Inc., announced that results from a phase 2 Visionary-MS long-term extension (“LTE”) study have been presented at the 2024 American Academy of Neurology (“AAN”) annual meeting. The data, which demonstrates improved clinical, functional and structural outcomes associated with daily oral dosing of CNM-Au8 30 mg. for up to three years…

Wednesday Apr 17, 2024 - 9:41 am

InvestorNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) in Process of Responding to Emergency Request for IV Suramin from African Health Ministry

PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, has received an urgent request from the Ministry of Health (“MOH”) of Malawi requesting emergency access to IV suramin. According to the announcement, Malawi officials requested the suramin in efforts to avert a potential humanitarian crisis brought on by dwindling supplies of drugs used in that region of Africa; the drug is…

Tuesday Apr 16, 2024 - 1:25 pm

InvestorNewsBreaks – QSAM Biosciences Inc. (QSAM) Announces Reverse Stock Split Ratio Ahead of Merger

QSAM Biosciences (OTCQB: QSAM) previously announced that it will effectuate a reverse stock split of the issued and outstanding shares of QSAM’s common stock, par value $0.0001 per share, at a ratio in the range of 1:1000 to 1:2000, prior to the closing of the merger between the company and Telix Pharmaceuticals Limited (ASX: TLX) (OTC: TLPPF), under which Telix will acquire QSAM. On April…

Tuesday Apr 16, 2024 - 10:28 am

InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Shares Positive Interim Results on IGC-AD1 for Agitation in Alzheimer’s

IGC Pharma (NYSE American: IGC), a company focused on developing innovative solutions to address Alzheimer’s disease, has announced that interim data from its phase 2 trial demonstrates a clinically significant reduction, approaching statistical significance, in agitation in Alzheimer’s at week two compared to placebo. IGC-AD1 targets neuroinflammation and CB1 receptor dysfunction, and the investigational drug contains THC, a principal psychoactive cannabinoid found in cannabis, as…

Monday Apr 15, 2024 - 1:18 pm

InvestorNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Represents Opportunity to Provide Solution for GBM Patients

CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biopharmaceutical company advancing its lead drug candidate, Berubicin, along the pathway to potential regulatory approval and commercialization, recently appointed Amy Mahery to its board of directors. “A biotech commercialization leader, Ms. Mahery has built an illustrious career that spans more than 20 years. During this period, she has gained commercial expertise working with small and large companies in common…

Monday Apr 15, 2024 - 12:53 pm

InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) to Share CLEAR MIND Study Results in Featured Research Oral Presentation at 2024 AAIC

Longeveron (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that it has been accepted for a Featured Research Oral Presentation to present the company’s CLEAR MIND Phase 2a study results. A Phase 2a randomized clinical trial, CLEAR-MIND is evaluating Lomecel-B(TM) in mild Alzheimer’s disease. In addition to the study results, Longeveron has been accepted for a poster presentation at the 2024…

Monday Apr 15, 2024 - 9:53 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Releases Update on Celly Nu Investment

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, is reporting on its investment in Celly Nutrition Corp. According to the report, FSA entered into a loan-amending agreement with Celly Nu that increased the principal of a previously announced term loan by $300,000, from $1 million…

Friday Apr 12, 2024 - 11:41 am

InvestorNewsBreaks – Sigyn Therapeutics Inc. (SIGY) Leveraging Portfolio to Overcome Current Limitations in Healthcare

Sigyn Therapeutics (OTCQB: SIGY), a medical technology that creates medical solutions to treat life-threatening conditions, is developing a portfolio of technologies, including Sigyn Therapy(TM), ChemoPrep(TM), ChemoPure(TM) and ImmunePrep(TM), which have each been designed to overcome a current limitation in healthcare. “As it relates to pathogen-associated disorders, the company has advanced Sigyn Therapy(TM) from concept through product development and subsequently completed five invitro blood purification studies,…

Friday Apr 12, 2024 - 9:52 am

InvestorNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Closes on Public Offering Valued at Estimated $5.2M

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty, has closed on its previously announced public offering. The offering was comprised of up to 2,234,043 shares of Class A LGVN common stock (or prefunded warrants in lieu thereof) and warrants to purchase up to 2,234,043 shares…

Friday Apr 12, 2024 - 9:33 am

InvestorNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Announces ‘Milestone Achievement’ on Journey to Developing PAX-101

PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, has completed the execution of three pivotal registration/validation batches of PAX-101, which is an IV formulation of suramin. According to the announcement, this is an important milestone achievement as the company works toward enabling a New Drug Application (“NDA”) submission to the U.S. Food and Drug Administration (“FDA”). Currently, the company anticipates…

Thursday Apr 11, 2024 - 3:45 pm

InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Looking to Advance Discussions for Accelerated Approval, New NDA for CNM-Au8(R) in 2024

Clene (NASDAQ: CLNN), alongside its wholly owned subsidiary Clene Nanomedicine Inc., is a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases. These include amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). “Clene’s lead candidate, CNM-Au8(R), is a gold nanocrystal suspension that has emerged as a promising candidate for the treatment of both ALS and MS… Despite the…

Thursday Apr 11, 2024 - 1:27 pm

InvestorNewsBreaks – Pressure BioSciences Inc. (PBIO) Subsidiary Plans Expansion to Successful New Premium Collection

Pressure BioSciences (OTCQB: PBIO) and its wholly owned subsidiary, Uncle Bud’s, are expanding the Premium Collection of state-of-the-art nanoemulsified products. The line of Premium Collection products combines innovation in performance and quality with a new generation of diverse nanoemulsion products that offer preservative-free, organic, “clean and green,” all-natural wellness solutions. The first product available under the Premium Collection brand was the exclusive Body Revive Spray…

Wednesday Apr 10, 2024 - 10:54 am

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) to Present at Bloom Burton & Co. Healthcare Conference

Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, announced that its CEO Doug Drysdale will present at the 2024 Bloom Burton & Co. Healthcare Investor Conference. The event is slated to take place April 16-17 in Toronto, Ontario. Drysdale’s presentation will be webcast live at 1:30 p.m. ET…

Wednesday Apr 10, 2024 - 9:42 am

InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Chief Science Officer to Present at This Month’s Europe Dermatology Drug Development Summit

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on the development of inflammation and immunology (“I&I”) biological products and on providing contract development and manufacturing organization (“CDMO”) services through its Scinai Bioservices business unit, will be featured at this month’s annual Dermatology Drug Development Summit Europe. During the three-day gathering, SCNI chief science officer Dr. Tamar Ben-Yedidia will discuss the company’s NanoAbs as a local treatment for plaque psoriasis;…

Wednesday Apr 10, 2024 - 9:29 am

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) CEO Discusses Medicare Reimbursement Approval for CARE Oral Medical Devices in Proactive Interview

Vivos Therapeutics (NASDAQ: VVOS), a leading medical-device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders, is spotlighted in a recent Proactive interview. During the interview, Vivos CEO Kirk Huntsman and Proactive host Steve Darling discuss the latest news from the company, which is the regulatory approval for Medicare reimbursement of oral medical devices designed for…

Wednesday Apr 10, 2024 - 9:15 am

InvestorNewsBreaks – Telo Genomics Corp. (TSX.V: TELO) (OTCQB: TDSGF) Notes Key Milestone with Award of College of American Pathologists Accreditation

Telo Genomics (TSX.V: TELO) (OTCQB: TDSGF),a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncology, has received accreditation for its Toronto-based laboratory at the MaRS Center from the Accreditation Committee of the College of American Pathologists (“CAP”). The accreditation followed more than a year of preparation and an on-site inspection by the CAP Accreditation Programs.…

Tuesday Apr 09, 2024 - 12:35 pm

InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Adds AI Expert to Support Development of Phase 2 Clinical Trial

IGC Pharma (NYSE American: IGC), a company focused on developing innovative solutions to address Alzheimer’s disease, has announced the addition of Pablo Arbelaez, Ph.D., an expert in artificial intelligence (“AI”) and one of the world’s top researchers. Dr. Arbelaez will support the development of the Phase 2 clinical trial of IGC Pharma’s lead therapeutic candidate IGC-AD1, targeting agitation in Alzheimer’s. “We welcome Dr. Pablo Arbelaez…

Tuesday Apr 09, 2024 - 11:04 am

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Achieves Milestone with CARE Oral Medical Devices Gaining Approval for Medicare Reimbursement

Vivos Therapeutics (NASDAQ: VVOS), a leading medical-device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders, has obtained all required regulatory approvals so that its CARE oral medical devices can be reimbursed by Medicare. Calling this a “milestone achievement,” the company noted that millions of Medicare beneficiaries can now use and be reimbursed for allowable charges…

Tuesday Apr 09, 2024 - 9:42 am

InvestorNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Releases Pricing for Mulitmillion-Dollar Public Offering

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty, has announced the pricing of its public offering. The offering is comprised of 2,234,043 shares of the company’s Class A common stock (or prefunded warrants) and warrants to purchase up to 2,234,043 shares of Class A common…

Monday Apr 08, 2024 - 11:07 am

InvestorNewsBreaks – Astrotech Corp. (NASDAQ: ASTC) Approved as US Government Vendor, Proprietary TRACER 1000 Listed on GSA

Astrotech (NASDAQ: ASTC), an innovative science and technology company, and its wholly owned subsidiary, 1st Detect Corporation, have announced that its TRACER 1000(TM) is now listed in the U.S. General Services Administration (“GSA”) IT Schedule 70, making the company an approved U.S. government vendor. The device can be found under Contract No. GS-35F-250GA with SRI Group LLC, Special Item Number 334290. According to the announcement, IT Schedule 70…

Friday Apr 05, 2024 - 11:59 am

InvestorNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Developing Robust Product Lineup to Address ASD, Associated Neurodevelopmental Conditions

PaxMedica (NASDAQ: PXMD) is a clinical-stage biopharmaceutical company focused on the development of novel anti-purinergic therapies (“APTs”) for the treatment of autism spectrum disorder (“ASD”) and other serious conditions with intractable neurologic symptoms. The company is on a promising path to address the unmet medical needs of ASD, bringing hope to millions. “ASD is a developmental disorder affecting how individuals interact with other people, behavior,…

Tuesday Apr 02, 2024 - 11:31 am

InvestorNewsBreaks – Astiva Health Setting New Standard for Patient-Centric Care

Astiva Health, a leading provider that specializes in delivering personalized and comprehensive healthcare solutions to diverse communities, is championing a model of care that emphasizes proactive health management and a healthy lifestyle over traditional reactive methods. “At the core of Astiva Health’s innovative approach is the principle of patient-centric care. This method prioritizes the active involvement of patients in their healthcare decisions, ensuring their preferences,…

Tuesday Apr 02, 2024 - 11:17 am

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Enters Acquisition Agreement to Acquire Biodefense Vaccine Developer

Aditxt (NASDAQ: ADTX), a company dedicated to discovering, developing and deploying promising health innovations, has signed a definitive arrangement agreement to acquire Appili Therapeutics Inc. (TSX: APLI) (OTCQX: APLIF). Appili is a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures. According to the agreement, Adivir Inc., a wholly owned subsidiary of Aditxt, will acquire all issued and outstanding Class A common shares…

Monday Apr 01, 2024 - 11:50 am

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Participate in Upcoming Investor Events

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be featured in two April investor conferences, including the MedInvest Biotech & Pharma Investor Conference and the 14th annual LD Micro Invitational. CNS Pharmaceuticals CEO John Climaco will present at the one-day MedInvest Biotech & Pharma Investor event,…

Monday Apr 01, 2024 - 10:18 am

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Q4, FY 2023 Financial Report, Operational Update

Vivos Therapeutics (NASDAQ: VVOS), a leading medical-device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders, is reporting financial results and operating highlights for Q4 and full year 2023, for the period ended Dec. 31, 2023. The report noted that revenue came in at $3.2 million for Q4 2023 and $13.8 million for the full year;…

Monday Apr 01, 2024 - 10:01 am

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Releases Year-End 2023 Financial Report, Business Update

Predictive Oncology (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial-intelligence (“AI”) and machine-learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility to accelerate oncologic drug discovery and enable drug development, is reporting on its financial and operating results for the year ended Dec. 31, 2023; the company also released a corporate update. The report noted POAI experienced a net loss of…

Wednesday Mar 27, 2024 - 1:50 pm

InvestorNewsBreaks – Sigyn Therapeutics Inc. (SIGY) Making Drugs Perform Better

Sigyn Therapeutics (OTCQB: SIGY), a medical technology company, is developing blood purification technologies to treat life-threatening conditions that are not addressed with current market-cleared drug agents as well as an expansive pipeline of technologies to optimize the benefit of cancer therapies. “The company’s lead product candidate, Sigyn Therapy(TM), is a single-use disposable device that is deployable on the global infrastructure of hemodialysis and continuous renal…

InvestorNewsBreaks

NewsBreak Category: Biotechnology

Get Started with InvestorWire

Press Distribution

Explore Press Distribution Solutions

Discover Add-on Solutions